T/Tn Antigen Vaccine is Effective and Safe in Preventing Recurrence of Advanced Human Breast Carcinoma

For nearly 20 yrs, we use T/Tn antigen vaccine in safe, specific, effective, long-term intradermal vaccination against recurrence of advanced breast carcinoma. Treatment is ad infinitum. All 18 breast carcinoma patients treated, pTNM Stages TV (6), III (6), and II (6), survived >5 yrs postoperatively; 10 survived >10 to >18 yrs; of the latter, three patients each are Stages III and TV. Five additional 5 yr survivors have not yet reached 10 yrs. The probability that our survival results are due to chance, with NCI "1991 Standard PDQ Data" as control, for all three stages taken together is: 5-yr survival: p<l x 10^-8; 10-yr survival: p<1 x 10^-5. There were no untoward side effects. The vaccination area presented as a delayed-type hypersensitivity reaction, but at variance with the PPD reaction, with significant inflammation, increase of helper T lymphocytes and decrease of the T suppressor/cytotoxic cell ratio.